This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

It has a strong antibacterial effect on most anaerobic bacteria. Its bactericidal mechanism has not been fully elucidated. The nitroreductase of anaerobic bacteria plays an important role in the energy metabolism of sensitive strains. The nitro group of this product is reduced to a cytotoxin, thereby acting on the DNA metabolism process of bacteria and promoting cell death. Resistant bacteria often lack nitroreductase and are therefore resistant to metronidazole.

It is a long-acting nonsteroidal anti-inflammatory analgesic. After entering the body, it is metabolized into diphenyl ethyl ester, which can inhibit the activity of cyclooxygenase, reduce the synthesis of prostaglandins, and produce anti-inflammatory, analgesic and antipyretic effects.

This product is a broad-spectrum antibacterial agent, with bactericidal effect at high concentration. It has certain antibacterial effect on Streptococcus pneumoniae, hemolytic Streptococcus, Streptococcus viridans and some Staphylococci, Clostridium perfringens, Bacillus anthracis, Yersinia pestis, Corynebacterium diphtheriae, Clostridium tetani, Brucella, Haemophilus influenzae, Campylobacter, Vibrio cholerae, and also has inhibitory effect on Rickettsia, Mycoplasma, Chlamydia, Spirochete, and some protozoa. It has better effect on Gram-positive bacteria than Gram-negative bacteria. The mechanism of action is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, preventing the connection of aminoacyl-tRNA at this position, thereby inhibiting the growth of peptide chains and affecting the synthesis of bacterial proteins.

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor.